Loading clinical trials...

Anabolic Therapy in Postmenopausal Osteoporosis | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE4

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590•Massachusetts General Hospital

Summary

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

Eligibility

Age

45 - No limit years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Postmenopausal women at high risk of fracture

Exclusion Criteria

•Prior therapy exclusions
•1. current use or use in the past 12 months of oral bisphosphonates or denosumab
•2. current use or use within the past 3 months of estrogens, SERMs, or calcitonin.
•3. use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months
•4. any current or previous use of romosozumab or strontium
•5. current use or use within the past 3 years of teriparatide, abaloparatide, or any parenteral bisphosphonate.
•Other exclusions
•1. Confirmed serum alkaline greater than 2 times the upper normal limit.
•2. Stage 4 or 5 chronic kidney disease (GFR less than 30)
•3. Hypercalcemia (Ca greater than 10.5 mg/dL)
+17 more criteria

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

March 24, 2022

Primary Completion Date

October 1, 2027

Completion Date

November 1, 2027

Last Updated

September 26, 2025

Enrollment

ACTUAL participants

Conditions

Postmenopausal Osteoporosis

Interventions

Romosozumab

DRUG

Denosumab

DRUG

AGE Burden and Response to Antiresorptive Therapy in Osteoporosis

NCT07329543

OsteoporosisPostmenopausal Osteoporosis

View study

WITHDRAWNNA

Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis

NCT05060380

OsteopeniaOsteoporosis+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 26, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Anabolic Therapy in Postmenopausal Osteoporosis

Inclusion Criteria

Exclusion Criteria

AGE Burden and Response to Antiresorptive Therapy in Osteoporosis

Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis

A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis

A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

Efficacy and Safety of Minodronate in Patients With Low Back Pain